Skip to main content
Tugce Munise Satir on Muck Rack

Tugce Munise Satir

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Tugce Munise

Contact Tugce Munise, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

The rise and fall of SARM1 base-exchange inhibitors

|
By Thomas Lundbäck, Vijay Chandrasekar, Robyn McAdam, Kasim Sader, Bradley Peter, Lisa Wissler, Philip Nevin, Edmund Foster, Tanguy Jamier, Jenny Sandmark, Mei Ding, Sanhita Mitra, Tugce Munise Satir, Bilada Bilican, Mirko Messa, Graham Fraser Verified, John E. Linley, Helen Plant, Rachel Moore, Tina Seifert, Michael Lerche, Nour Majbour, Taiana Maia de Oliveira, Qi Wang, Perla Breccia, Rebecca Jarvis Verified, Chendi Gu, Hyoungseok Ju, Maria Palomero, Pravallika Manjappa, Carina Johansson, Anette Persson-Kry, Carina Raynochek, Ewa Nilsson, Richard Lucey, Iain Chessell
| Nature Verified
Abstract The sterile alpha and TIR motif containing 1 (SARM1) enzyme is a key driver of axonal degeneration in response to injury, making it an attractive target for treating chemotherapy-induced peripheral neuropathy (CIPN) and other nervous system diseases. In this study, we identified and optimised a class of base-exchange inhibitors (BEXi) targeting human SARM1 and explored their molecular interactions and conformational effects using cryo-EM, HDX-MS and SAXS.
Open in Who Shared Issue with article?

Customizable virus-like particles deliver CRISPR–Cas9 ribonucleoprotein for effective ocular neovascular and Huntington’s disease gene therapy - Nature Nanotechnology

|
By Zhuofan Jiang, Jianping Liu, Niklas Selfjord, Pinar Akcakaya, Jiaxu Hong, Sicong Lu, Tugce Munise Satir
| Nature Verified
Abstract In vivo CRISPR gene editing holds enormous potential for various diseases. Ideally, CRISPR delivery should be cell type-specific and time-restricted for optimal efficacy and safety, but customizable methods are lacking. Here we develop a cell-tropism programmable CRISPR–Cas9 ribonucleoprotein delivery system (RIDE) based on virus-like particles. The efficiency of RIDE was comparable to that of adeno-associated virus and lentiviral vectors and higher than lipid nanoparticles.
Open in Who Shared Issue with article?
See all 2 articles